Pharma innovation up or down?

Mirasol, Feliza
October 2007
ICIS Chemical Business;10/15/2007, Vol. 272 Issue 14, p23
Trade Publication
The article discusses the innovation in the pharmaceutical industry in the coming years. The estimates record a decline in the new molecular entities approved by the U.S. Food and Drug Administration since the last seven years. Whereas growth in research and development pipeline still seems to be strong specially in the number of product candidates in Phase I and Phase II clinical development. A report by PricewaterhouseCoopers estimates a good growth in the pharmaceutical market by 2020.


Related Articles

  • Endpoint Research.  // Applied Clinical Trials;Dec2005, Vol. 14 Issue 12, p116 

    This article presents information about the Contract Research Organization, Endpoint Research. It was established in 1990. Endpoint provides a full range of contract services and resources in order to assure expedited clinical development and successful submission to the U.S. Food and Drug...

  • FDA, Research Organizations Seek to Bolster Drug Submissions. Wechsler, Jill // Applied Clinical Trials;Sep2013, Vol. 22 Issue 9, p12 

    The article informs that the U.S. Food and Drug Administration (FDA) has increased fees paid by pharma and biotech firms for 2014 authorized by the Prescription Drug User Fee Act (PDUFA). It states that decline in anticipated New Drug Applications (NDAs) submitted to the FDA can result in...

  • News Update.  // Applied Clinical Trials;Sep2000, Vol. 9 Issue 9, p14 

    Reports developments related to clinical trials in the United States as of September 2000. Approval of several health-related drugs by the Food and Drug Administration; Results of clinical trials on cancer and hypertension treatment; Details on the approval of the orphan drug status to Cell...

  • In Vitro to the Rescue. Bode, Chris // Applied Clinical Trials;Jun2008, Vol. 17 Issue 6, p180 

    The article focuses on the importance of the Critical Path Initiative developed by the U.S. Food and Drug Administration (FDA) for the vitro Absorption, Distribution, Metabolism and Excretion (ADME) models. The scheme will modernize and speed up the development process which will focus on...

  • Pediatric Mandate. Keeney, Ronald // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p98 

    Explores how the pharmaceutical industry of the United States (U.S.) can change its approach to pediatric clinical trials in line with the U.S. Food and Drug Administration's (FDA) regulations mandating pediatric studies for drugs and biologicals. FDA initiatives in line with the issue of...

  • Pediatric Safety Rule Momentum in Congress.  // Chemical Market Reporter;1/6/2003, Vol. 263 Issue 1, p7 

    Reports on a legislation giving the U.S. Food and Drug Administration authority to require pharmaceutical companies to conduct clinical trials to determine whether drugs and biologics are safe and effective in children. Incentives given by the Best Pharmaceutical for Children Act for drug makers.

  • More Funds Needed Abroad. Drakulich, Angie // Pharmaceutical Technology;Jan2008, Vol. 32 Issue 1, p23 

    The article reports on the increased funding needed by the U.S. Food and Drug Administration (FDA) for overseas drug inspection. FDA announces that a total of $16 million is needed for foreign inspection and $56 million is required with the integration of domestic drug inspection. However, it...

  • Process Validation. Levenson, Michele; Chatterjee, Bikash // Pharmaceutical Processing;Jul/Aug2013, Vol. 28 Issue 6, p42 

    The article focuses on the New Process Validation Guidance issued by the U.S. Food and Drug Administration (FDA). Implementing an effective verification and control strategy to ensure process and product performance is important in the new Process Validation Guidance. The new guidance departs...

  • Manufacturers optimistic ahead of FDA review. Houlton, Sarah // Chemical Week;2/19/2003, Vol. 165 Issue 7, p30 

    Reports on the optimism of drug manufacturers on the drug approval rate by the U.S. Food and Drug Administration (FDA) for the year 2003. Goal of the drug review of the FDA; Changes in the pharmaceutical sector; Factors the contributed to the decline of the drug approval rate.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics